Introduction: The aim of this study was to identify preoperative risk factors for poor survival in patients with resectable pancreatic ductal adenocarcinoma (PDAC) treated with upfront surgery. Methods: Medical records of 268 patients with resectable PDAC defined by resectability status who underwent upfront surgery were reviewed retrospectively. Multivariate analyses were performed to identify preoperative risk factors for recurrence-free survival (RFS) and overall survival (OS). Moreover, a binary logistic regression model was built to determine preoperative independent risk factors of 2- and 3-year recurrence and survival. Results: Multivariate analyses identified CA19-9 (≥100 U/mL, p < 0.001) as an independent risk factor for poor RFS, and worse performance status (1 or 2, p = 0.03), platelet:lymphocyte ratio (<150, p = 0.04), and preoperative CA19-9 (≥100 U/mL, p < 0.001) as independent risk factors for poor OS. Moreover, preoperative CA19-9 (≥100 U/mL) was the only independent risk factor identified for 2- and 3-year recurrence and survival. Discussion/Conclusion: Preoperative CA19-9 (≥100 U/mL) was the most reliable preoperative predictive factor for poor survival in resectable PDAC treated with upfront surgery. These findings warrant further clinical trials investigating efficacy of neoadjuvant therapy targeting the subset of patients with resectable PDAC who have elevated preoperative CA19-9, namely, those with high risk of poor prognosis.

1.
Siegel
RL
,
Miller
KD
,
Jemal
A
.
Cancer statistics, 2020
.
CA Cancer J Clin
.
2020 Jan
;
70
(
1
):
7
30
.
2.
Statistics graph database. 2020 Jun 1. Available from: https://ganjoho.jp/reg_stat/statistics/stat/summary.html.
3.
National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology (NCCN Guidelines). 2020 Feb 1. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
4.
Mokdad
AA
,
Minter
RM
,
Zhu
H
,
Augustine
MM
,
Porembka
MR
,
Wang
SC
,
Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis
.
J Clin Oncol
.
2017 Feb 10
;
35
(
5
):
515
22
. .
5.
Oba
A
,
Croce
C
,
Hosokawa
P
,
Meguid
C
,
Torphy
RJ
,
Al-Musawi
MH
,
Prognosis based definition of resectability in pancreatic cancer: a road map to new guidelines
.
Ann Surg
.
2020 Mar 6
.
6.
Unno
M
,
Motoi
F
,
Matsuyama
Y
,
Satoi
S
,
Matsumoto
I
,
Aosasa
S
,
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05)
.
J Clinl Oncol
.
2019
;
37
:
189
.
7.
Brierley
J
,
Gospodarowicz
MK
,
Wittekind
C
.
TNM classification of malignant tumours
.
2017
.
8.
Bhatti
I
,
Peacock
O
,
Lloyd
G
,
Larvin
M
,
Hall
RI
.
Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio
.
Am J Surg
.
2010 Aug
;
200
(
2
):
197
203
. .
9.
Ikeguchi
M
,
Hanaki
T
,
Endo
K
,
Suzuki
K
,
Nakamura
S
,
Sawata
T
,
C-reactive protein/albumin ratio and prognostic nutritional index are strong prognostic indicators of survival in resected pancreatic ductal adenocarcinoma
.
J Pancreat Cancer
.
2017
;
3
(
1
):
31
6
. .
10.
Abe
T
,
Nakata
K
,
Kibe
S
,
Mori
Y
,
Miyasaka
Y
,
Ohuchida
K
,
Prognostic value of preoperative nutritional and immunological factors in patients with pancreatic ductal adenocarcinoma
.
Ann Surg Oncol
.
2018 Dec
;
25
(
13
):
3996
4003
. .
11.
Lee
BM
,
Chung
SY
,
Chang
JS
,
Lee
KJ
,
Seong
J
.
The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are prognostic factors in patients with locally advanced pancreatic cancer treated with chemoradiotherapy
.
Gut Liver
.
2018 May 15
;
12
(
3
):
342
52
. .
12.
Nakamura
T
,
Asano
T
,
Okamura
K
,
Tsuchikawa
T
,
Murakami
S
,
Kurashima
Y
,
A preoperative prognostic scoring system to predict prognosis for resectable pancreatic cancer: who will benefit from upfront surgery?
J Gastrointest Surg
.
2019 May
;
23
(
5
):
990
6
. .
13.
Sakoda
T
,
Uemura
K
,
Kondo
N
,
Sumiyoshi
T
,
Okada
K
,
Seo
S
,
Prognostic value of peritoneal lavage cytology in patients with pancreatic ductal adenocarcinoma stratified by the resectability status
.
J Gastrointest Surg
.
2021 Mar 25
. .
14.
Yamada
S
,
Fujii
T
,
Yabusaki
N
,
Murotani
K
,
Iwata
N
,
Kanda
M
,
Clinical implication of inflammation-based prognostic score in pancreatic cancer: glasgow prognostic score is the most reliable parameter
.
Medicine
.
2016 May
;
95
(
18
):
e3582
. .
15.
Riauka
R
,
Ignatavicius
P
,
Barauskas
G
.
Preoperative platelet to lymphocyte ratio as a prognostic factor for resectable pancreatic cancer: a systematic review and meta-analysis
.
Dig Surg
.
2020
;
37
(
6
):
447
55
. .
16.
Matsumoto
I
,
Murakami
Y
,
Shinzeki
M
,
Asari
S
,
Goto
T
,
Tani
M
,
Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: a multi-center retrospective study
.
Pancreatology
.
2015 Nov–Dec
;
15
(
6
):
674
80
. .
17.
Nakagawa
K
,
Sho
M
,
Akahori
T
,
Nagai
M
,
Nakamura
K
,
Takagi
T
,
Significance of the inflammation-based prognostic score in recurrent pancreatic cancer
.
Pancreatology
.
2019 Jul
;
19
(
5
):
722
8
. .
18.
Isaji
S
,
Mizuno
S
,
Windsor
JA
,
Bassi
C
,
Fernández-Del Castillo
C
,
Hackert
T
,
International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
.
Pancreatology
.
2018 Jan
;
18
(
1
):
2
11
. .
19.
Hartwig
W
,
Strobel
O
,
Hinz
U
,
Fritz
S
,
Hackert
T
,
Roth
C
,
CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy
.
Ann Surg Oncol
.
2013 Jul
;
20
(
7
):
2188
96
. .
20.
Zhou
G
,
Liu
X
,
Wang
X
,
Jin
D
,
Chen
Y
,
Li
G
,
Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort
.
Onco Targets Ther
.
2017
;
10
:
1199
206
. .
21.
Suzuki
S
,
Shimoda
M
,
Shimazaki
J
,
Maruyama
T
,
Oshiro
Y
,
Nishida
K
,
Predictive early recurrence factors of preoperative clinicophysiological findings in pancreatic cancer
.
Eur Surg Res
.
2018
;
59
(
5–6
):
329
38
. .
22.
Kim
WJ
,
Lim
TW
,
Park
PJ
,
Choi
SB
,
Kim
WB
.
Prognostic impact of the combination of the neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 in patients with pancreas head cancer
.
ANZ J Surg
.
2019 Jul
;
89
(
7–8
):
E302
e07
. .
23.
Conroy
T
,
Desseigne
F
,
Ychou
M
,
Bouché
O
,
Guimbaud
R
,
Bécouarn
Y
,
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
.
N Engl J Med
.
2011 May 12
;
364
(
19
):
1817
25
. .
24.
Von Hoff
DD
,
Ervin
T
,
Arena
FP
,
Chiorean
EG
,
Infante
J
,
Moore
M
,
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
.
N Engl J Med
.
2013 Oct 31
;
369
(
18
):
1691
703
. .
25.
Kondo
N
,
Murakami
Y
,
Uemura
K
,
Sudo
T
,
Hashimoto
Y
,
Nakagawa
N
,
A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma
.
Cancer Chemother Pharmacol
.
2017 Apr
;
79
(
4
):
775
81
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.